Novembro 2021: The first clinical trial of South Korea’s homegrown next-generation chimeric antigen receptor T (CAR-T) cell therapy, which is designed to circumvent immune checkpoint signals, has recently gotten under way.
O Instituto Avançado de Ciência e Tecnologia da Coreia (KAIST) anunciou na quarta-feira que um ensaio clínico de Fase 1b de sua terapia com células CAR-T está sendo conduzido no Samsung Medical Center em Seul. O estudo está sendo conduzido com 10 pacientes coreanos com linfoma difuso de grandes células B recidivante e refratário. Os direitos de comercialização do oleoduto foram transferidos da universidade para a empresa Curocell, co-fundada pelo professor Kim Chan-hyuk. A Curocell é responsável pelo programa de desenvolvimento clínico do revolucionário Imunoterapia.
In addition, a Phase 2 ensaio clínico involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for receptor de antígeno quimérico T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Você pode ler: Terapia com células T CAR na Coreia
Os resultados do estudo foram apresentados em um artigo que foi publicado online na edição de outubro da Molecular Therapy.
